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miquimod is an immune-response modifier avail-
able as a 5% cream for treating external anogeni-
tal warts. Demonstrated to exert antiviral activity
by stimulating a local immune response, imi-
quimod 5% cream offers an effective, nonablative
alternative to current treatments.
IMIQUIMOD CREAM: INDICATION
Imiquimod (AldaraTM, 3M Pharmaceuticals, St.
Paul, MN) is an immune-response modifier. In the
United States, it is currently indicated for the treat-
ment of external anogenital warts. Available in a
5% cream, it is applied by the patient to the warts
and adjacent skin three times a week (e.g., Mon-
day, Wednesday, and Friday or Tuesday, Thurs-
day, and Saturday) for up to 16 weeks until warts
are gone.
STRUCTURE AND DERIVATION
Imiquimod (1-(2-methylpropyl)-lH-imidazo[4,5-
c]quinolin-4-amine) has a structural formula indica-
tive of a novel compound.
MECHANISM OF ACTION
The mechanism of action of imiquimod in treating
genital and perianal warts is unknown. It has no
direct antiviral activity in cell culture. Studies in
human peripheral blood mononuclear cells
(PBMCs) suggest that imiquimod induces cyto-
kines, including interferon-o, interleukins, and tu-
mor necrosis factor. 1,e Additionally, results of a ve-
hicle-controlled clinical trial demonstrated that ap-
plication of imiquimod 5% cream induced local
production of interferon and reduced the viral load
of human papillomavirus (HPV) subtypes 6 and
11.-
PHARMACOKINETICS
Minimal systemic absorption of imiquimod
through intact skin occurs during treatment with
topically applied imiquimod 5% cream. Clinical
studies showed no quantifiable concentrations of
imiquimod or metabolites in serum, and <0.9% of a
single 5-mg dose was excreted in urine and feces.
SIDE EFFECTS AND INTERACTIONS
Imiquimod 5% cream is generally well tolerated.
The most common adverse events occurred at the
wart site and were mild to moderate in intensity.
Discomfort was reported by fewer than 50% of pa-
tients receiving imiquimod 5% cream during clini-
cal trials, and fewer than 2% discontinued therapy
because of adverse events. The most common ap-
plication-site reactions reported at least once by
women were itching (32%), burning (26%), pain
(8%), and soreness (3%).
Treatment with imiquimod 5% cream is also as-
sociated with local skin reactions, the most com-
mon of which, in female patients, were erythema
(65%), erosion (31%), excoriation/flaking (18%),
edema (18%), ulceration (8%), and induration (5%)
at the wart site. Erythema is characteristic of a
local immune response.
Imiquimod 5% cream is rated Pregnancy Cat-
egory B. There arc no adequate and well-
controlled studies of imiquimod 5% cream in preg-
nant women. Additionally, safety and efficacy in
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TABLE I. Cost of treating genital warts
Treatment Length of course Average cost
Imiquimod
AldaraTM cream
Podofilox
Condylox(R) solution
Condylox(R) gel
Cryotherapy
Podophyllin
Trichloroacetic acid
Electrosurgery
Laser
Surgical excision
4 to 16 weeks/I visit $178-$502
Up to 4 weeks/I visit
Up to 4 weeks/I visit
to 4 in-office treatments
to 6 in-office treatments
to 6 in-office treatments
in-office treatment
to 3 in-office treatments
in-office treatment
$132
$127
$209-$871
$138-$574
$138-$574
$270-$340
d,e
$305-$2650
d,e,f
$282
aAssumes average wholesale price plus cost of office visits @ $70 per visit.
bMedi-Span, Inc. Prescription Pricing Guide. Indianapolis, IN, January 1998.
cStrauss MJ, Khanna V, Koenig JD, et al.: The cost of treating genital warts. Int Dermatol 35:340-348, 1996.
dMayeaux, Harper MB, Barksdale W, Pope JB: Noncervical human papillomavirus genital infections. Am Fam Physician 52:1137-1146, 1995.
eKraus SJ, Stone KM: Management of genital infection caused by human papillomavirus. Rev Infect Dis 12(suppl 6):$620-$632, 1990.
flncludes surgeon and anesthesiologist. Hospitalization would be assumed to require an additional $500 to $600 per day.
patients below the age of 18 years old have not
been established.
SPECTRUM OF ANTIVIRAI_ ACTIVITY
Imiquimod has no direct antiviral effect. Indirect
antiviral activity has been demonstrated in cell cul-
ture models and in several animal infection models.
In vitro induction of interferons and other cyto-
kines was demonstrated in imiquimod-stimulated
PBMC culture, e Additionally, imiquimod antiviral
activity against herpes simplex virus,4-7 cytomega-
lovirus,8 and Rift Valley fever virus (a bunyavirus)
9
has also been demonstrated in animal models.
CLINICAL APPLICATIONS
Imiquimod 5% cream is currently approved to treat
external genital and perianal warts. The Centers
for Disease Control and Prevention recommends
that physicians have at least one patient-applied
treatment option for the treatment of external geni-
tal and perianal warts.1 Patients apply imiquimod
5% cream at bedtime three times a week until
warts are gone or for as long as 16 weeks. The
treated area should be washed with mild soap and
water 6 to 10 hours after application. Many patients
may be clear of warts after 8 to 10 weeks or sooner.
Patients should be informed that new warts may
develop during treatment, that the effect of imi-
quimod 5% cream on the transmission of genital
warts is unknown, and that, because imiquimod 5%
cream may weaken latex condoms and diaphragms,
sexual contact should be avoided while the cream
is on the skin.
The efficacy and safety of imiquimod 5% cream
were evaluated in multicenter, double-blind, ran-
domized, vehicle-controlled, parallel-design trials.
Approximately 900 male and female patients with
external genital and/or perianal warts have been
evaluated in a clinical trial setting with imiquimod
5% cream.
Randomized, vehicle-controlled trials have
demonstrated significantly greater wart clearance
rates with imiquimod 5% cream, compared with
vehicle or imiquimod 1% cream. In the largest of
these trials, a phase-three trial of 311 patients, imi-
quimod 5% cream was significantly more effective
than either imiquimod 1% cream or vehicle in
clearing genital and perianal warts. Complete clear-
ance was achieved by 72% of women and 33% of
men, while >50% of warts cleared in 85% of
women and 70% of men in the 16-week treatment
period. Of those patients whose warts cleared com-
pletely, 44% were clear by week 8 of treatment and
69% were clear by week 12.1
COST
Table represents the average cost of treating
genital warts. Because most treatments for genital
warts are in-office procedures, costs were calcu-
lated by combining the cost of the average number
of office visits with the average wholesale price of
treatments.
CONCLUSIONS
Imiquimod is a novel chemical compound; no
chemically similar compounds are indicated for hu-
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man use. The proven efficacy, minimal systemic
exposure, acceptable local adverse-event profile,
lack of drug-related pharmacologic effects, and low
potential for overdose make imiquimod 5% cream
a safe, first-line, patient-applied therapy for treat-
ing external genital and perianal warts.
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